- NeuroOne Medical Technologies Corporation (NMTC, Financial) improved gross margins to 55.6% in Q2 FY2025, up from 28.3% YoY.
- H1 FY2025 product revenue surged by 98% to $4.7 million.
- Secured $8.2 million in oversubscribed capital raise, ensuring full funding through FY2026.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) reported significant financial and operational advancements in the second quarter of fiscal year 2025. The company's gross margin soared to 55.6% from 28.3% in the same quarter last year, indicating substantial improvements in manufacturing efficiency. While Q2 product revenue remained flat at $1.4 million, the company saw a remarkable 98% increase in product revenue for the first half of the fiscal year, reaching $4.7 million.
Operationally, NeuroOne successfully filed an FDA submission ahead of schedule for its OneRF® Trigeminal Nerve Ablation System. This advancement is set to potentially generate new revenue streams by late 2025, pending FDA clearance. Moreover, the company completed an $8.2 million capital raise in April 2025, which was oversubscribed, securing their financial stability through at least fiscal year 2026 without incurring any debt.
The company reaffirmed its fiscal year 2025 product revenue guidance, projecting between $8.0 million and $10.0 million, which represents a growth of 132% to 190% year-over-year. NeuroOne's enhancements are coupled with strategic hires, notably Dr. Parag Patil as Chief Medical Advisor, underscoring the company's commitment to clinical excellence and market expansion.
NeuroOne continues to advance its operational footprint, planning a post-market registry to collect outcome data, and is in discussions with strategic partners for additional applications of its patented OneRF® System, including spinal cord and sEEG-based therapies.
